The Return of High-Touch Claims Management

Technology has become table stakes. What's scarce is an experienced person who owns the file.

Every metric on the quarterly scorecard is green. Closure rates, contact timeliness, filing compliance, reporting cadence, all within target. The review takes forty minutes, and nobody raises a concern.

Then the risk manager asks about one file. A soft-tissue injury from fourteen months ago that has quietly become a six-figure exposure. Who owns it? How many adjusters has it been through? What's the plan?

The scorecard was never built to answer that question.

What We See in Our Own Book

Across the claims we administer, the cost pressure is rarely arriving through the front door. It arrives through channel, utilization, and steering — none of which show up on a closure-rate report.

Pharmacy is the clearest illustration. In our 2026 data, a physician-dispensed prescription averages $864 against $189 retail — a 457% premium for the same drug. A compounded script averages $1,260 against a $327 non-compound average. A topical dispensed from the prescriber's office averages $1,879 against $301 from a retail pharmacy. Where state rules permit in-office dispensing, roughly 10% of scripts go that route and average cost runs $348 versus $228 where it is barred.

Nothing about that is an inflation story. It's a story about who is directing care, and whether anyone is looking.

The same pattern holds on the legal side. The claims that break reserves often aren't the most severely injured; they're the most steered: represented from day one, treated at a small set of familiar clinics, with demands that arrive late and oversized.

That is the problem the last decade of efficiency investment didn't solve. The industry automated the routine claims, concentrated the hard ones on a smaller and more senior bench, and kept grading itself on volume.

Technology Didn't Close the Gap

Claims professionals still weigh significance; SIU still evaluates risk, and investigators develop the evidence. A model can tell you a claim is trending toward litigation with real accuracy. It cannot call the injured worker who hasn't heard from anyone in three weeks and is starting to think nobody is on their side. That conversation often determines whether the prediction comes true.

Technology has become table stakes. What's scarce is the thing it was supposed to make unnecessary: an experienced person who owns the file and is accountable for where it lands.

What That Looks Like in Practice

Supervisors carry no caseloads. Their role is oversight, coaching, reserve discipline, and strategic direction — not managing their own files while reviewing yours. Indemnity claims receive supervisor review within 15 days of assignment, again at 60 days, and every 90 days until resolution, with documented commentary on reserve accuracy at each review.

Reserves are set to realistic value, not stair-stepped. Rationale is documented in the file log and visible in RadiusR, and clients are consulted on every change above an agreed threshold. This is a deliberate departure from TPAs that stair-step upward or apply a static reserve by injury type.

Escalation happens at first notice. A proprietary severity model evaluates 45 data points at FNOL to route complex files to senior professionals before cost develops. Technology feeds the judgment rather than substituting it.

Clinical oversight is embedded, not bolted on. Nurse triage, case management, utilization review, pharmacy, network, and bill review operate under one model with shared data and shared accountability. It begins with RN assessment at the point of injury.

Experience is on the file. Claims professionals average 12 years of handling experience, with roughly 15% of employees promoted annually and a 1% vacancy rate.

Someone answers. More than 55,000 calls a month, 100% domestic staff, 20-second average answer speed, 99% completion rate.

The proof is in the files nobody flagged. Every script whether it be retail, physician-dispensed, or out-of-network, is adjudicated against Lodestar rules before payment, with clinical review aimed at compounds and high-cost topicals. In that environment, the differentiator isn't the dashboard. It's whether someone experienced is holding the file — and whether you know their name.